Latest news with #Servier
Malaysian Reserve
3 days ago
- Business
- Malaysian Reserve
Servier Ranked Among Top Companies Across Several Categories in 2024 PatientView Corporate Reputation of Pharma Survey
Servier U.S. ranked #1 across several categories U.S. recognition follows last month's announcement that Servier made the top ten list of organizations evaluated by PatientView globally BOSTON, May 28, 2025 /PRNewswire/ — Servier today announced that the company was ranked among the top companies across several categories in PatientView's 2024 Corporate Reputation of Pharma in the U.S. survey. This annual survey captures insights from more than 350 patient organizations reflecting their firsthand experiences, perceptions and familiarity with pharmaceutical companies. This ranking comes on the heels of PatientView's Global Reputation of Pharma Survey – where Servier earned a spot in the Top 10 of pharmaceutical company reputations among patient organizations. This marked the first time in the Top 10 globally, reinforcing our ever-increasing commitment to patients and the organizations that represent them. 'Being recognized at the top of PatientView's annual rankings is not just an honor, it's a meaningful reflection of our continued commitment to listening to patients, collaborating closely with patient advocates, and delivering solutions that truly meet needs,' said Nicolas Garnier, Chief Patient Officer, Servier. 'This recognition is a reflection of our deep, ongoing commitment to putting patients first and acknowledging the essential role they play in shaping our work at every stage. This kind of external validation reinforces that we are listening, learning, and taking the right actions to truly support patients and the communities that represent them.' U.S. patient organizations also ranked Servier in the top two across all categories and first in several categories: Transparency on Data, Integrity, Beyond the Pill, Engagement in R&D. Globally, Servier was also ranked among the top 10 companies – underscoring the company's growing reputation and meaningful impact on patients worldwide. 'At Servier, engaging meaningfully with patient organizations and ensuring access to medicines are fundamental priorities,' said Wendy Poage, Vice President of the Patient Office at Servier. 'We're honored to be recognized in the Patient View report for our integrity and commitment to delivering support that goes beyond the pill. This kind of external validation reinforces that we are listening, learning, and taking the right actions to truly support patients and the communities that represent them.' For more information on Servier Pharmaceuticals patient support services, please visit and About the Corporate Reputation of Pharma Survey 2024 'Corporate Reputation of Pharma' survey of patient groups worldwide was conducted December 2024 to March 2025 and answered by 372 US patient groups, representing over 13 million US patients during the past year. The PatientView annual Corporate Reputation of Pharma survey gives patient-advocacy groups an opportunity to comment on, and assess, the pharma industry's performance. Companies are ranked against their peers. The survey results reinforce the dedication, commitment and hard work companies invest internally to ensure engagement with patients and advocacy groups is reflective of the patients they serve. About Servier Servier is a global pharmaceutical group governed by a nonprofit foundation, committed to making a meaningful social impact for patients and contributing to a sustainable world. Its unique governance model ensures its independence, while supporting long-term innovation, with 100% of its profits reinvested in the Group's development. As a world leader in hypertension and venous diseases and major player in cardiometabolism, Servier drives transformative innovation to support patients with chronic conditions and improve their day-to-day lives through a holistic approach, which includes making patient adherence and control a priority across the globe. Its ambition is to become a leading player in rare cancers, which is why the Group invests heavily in oncology, allocating close to 70% of its R&D budget to this field. By leveraging precision medicine, Servier develops therapies that are more targeted and more effective. Bolstered by its success in oncology, Servier has expanded into neurology, a key driver of future growth. The Group is focused on a select number of neurodegenerative diseases, where accurate patient profiling enables targeted therapeutic responses through precision medicine. To open up wider access to high-quality, affordable care, Servier also offers an extensive range of generic medicines, building on well-established brands in France, Eastern Europe, and Brazil. In all its activities, and at every stage of the medicine life cycle, the Group integrates the patient's voice. Headquartered in France, Servier operates in around 140 countries. In 2023-2024, the Group, which employs over 22,000 people worldwide, achieved revenues of €5.9 billion. More information on our website : Follow us on social media : LinkedIn, Facebook, Twitter, Instagram Media Contact: Sara Noonan
Yahoo
3 days ago
- Business
- Yahoo
Servier Ranked Among Top Companies Across Several Categories in 2024 PatientView Corporate Reputation of Pharma Survey
Servier U.S. ranked #1 across several categories U.S. recognition follows last month's announcement that Servier made the top ten list of organizations evaluated by PatientView globally BOSTON, May 28, 2025 /PRNewswire/ -- Servier today announced that the company was ranked among the top companies across several categories in PatientView's 2024 Corporate Reputation of Pharma in the U.S. survey. This annual survey captures insights from more than 350 patient organizations reflecting their firsthand experiences, perceptions and familiarity with pharmaceutical companies. This ranking comes on the heels of PatientView's Global Reputation of Pharma Survey – where Servier earned a spot in the Top 10 of pharmaceutical company reputations among patient organizations. This marked the first time in the Top 10 globally, reinforcing our ever-increasing commitment to patients and the organizations that represent them. "Being recognized at the top of PatientView's annual rankings is not just an honor, it's a meaningful reflection of our continued commitment to listening to patients, collaborating closely with patient advocates, and delivering solutions that truly meet needs," said Nicolas Garnier, Chief Patient Officer, Servier. "This recognition is a reflection of our deep, ongoing commitment to putting patients first and acknowledging the essential role they play in shaping our work at every stage. This kind of external validation reinforces that we are listening, learning, and taking the right actions to truly support patients and the communities that represent them." U.S. patient organizations also ranked Servier in the top two across all categories and first in several categories: Transparency on Data, Integrity, Beyond the Pill, Engagement in R&D. Globally, Servier was also ranked among the top 10 companies - underscoring the company's growing reputation and meaningful impact on patients worldwide. "At Servier, engaging meaningfully with patient organizations and ensuring access to medicines are fundamental priorities," said Wendy Poage, Vice President of the Patient Office at Servier. "We're honored to be recognized in the Patient View report for our integrity and commitment to delivering support that goes beyond the pill. This kind of external validation reinforces that we are listening, learning, and taking the right actions to truly support patients and the communities that represent them." For more information on Servier Pharmaceuticals patient support services, please visit and About the Corporate Reputation of Pharma Survey 2024 'Corporate Reputation of Pharma' survey of patient groups worldwide was conducted December 2024 to March 2025 and answered by 372 US patient groups, representing over 13 million US patients during the past year. The PatientView annual Corporate Reputation of Pharma survey gives patient-advocacy groups an opportunity to comment on, and assess, the pharma industry's performance. Companies are ranked against their peers. The survey results reinforce the dedication, commitment and hard work companies invest internally to ensure engagement with patients and advocacy groups is reflective of the patients they serve. About Servier Servier is a global pharmaceutical group governed by a nonprofit foundation, committed to making a meaningful social impact for patients and contributing to a sustainable world. Its unique governance model ensures its independence, while supporting long-term innovation, with 100% of its profits reinvested in the Group's development. As a world leader in hypertension and venous diseases and major player in cardiometabolism, Servier drives transformative innovation to support patients with chronic conditions and improve their day-to-day lives through a holistic approach, which includes making patient adherence and control a priority across the globe. Its ambition is to become a leading player in rare cancers, which is why the Group invests heavily in oncology, allocating close to 70% of its R&D budget to this field. By leveraging precision medicine, Servier develops therapies that are more targeted and more effective. Bolstered by its success in oncology, Servier has expanded into neurology, a key driver of future growth. The Group is focused on a select number of neurodegenerative diseases, where accurate patient profiling enables targeted therapeutic responses through precision medicine. To open up wider access to high-quality, affordable care, Servier also offers an extensive range of generic medicines, building on well-established brands in France, Eastern Europe, and Brazil. In all its activities, and at every stage of the medicine life cycle, the Group integrates the patient's voice. Headquartered in France, Servier operates in around 140 countries. In 2023-2024, the Group, which employs over 22,000 people worldwide, achieved revenues of €5.9 billion. More information on our website : Follow us on social media : LinkedIn, Facebook, Twitter, Instagram Media Contact: Sara Noonan View original content to download multimedia: SOURCE Servier Pharmaceuticals Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Citizen
13-05-2025
- Health
- The Citizen
Locals urged to check their blood pressure this May
Locals urged to check their blood pressure this May This May Measurement Month, health experts are sounding the alarm on hypertension (HTN), a condition that affects billions worldwide yet remains dangerously underdiagnosed and undertreated. Alarmingly, a recent study found that 74% of patients are unaware that they are at risk of hypertension or are unaware of their hypertension status. World Hypertension Day is observed on May 17. ALSO READ: Foundation calls for mental health support in gamblers HTN is the most significant risk factor for cardiovascular disease (in SA. With cardiovascular disease ranking among the top 10 causes of death worldwide, detecting and controlling blood pressure has never been more critical. Uncontrolled hypertension can lead to serious health complications, significantly increasing the risk of heart attack, stroke, kidney failure and heart failure. It's also linked to a higher likelihood of developing dementia and can drastically reduce overall quality of life. These consequences contribute to increased mortality and morbidity, underscoring the importance of early detection, treatment and management of high blood pressure. May Measurement Month A public health campaign, Because I Say So is part of a global blood pressure screening initiative, May Measurement Month. ALSO READ: Use suggestion boxes to raise concerns at healthcare facilities – City Now in its ninth year, this collaborative campaign was initiated in response to the hypertension health crisis. It is led by the International Society of Hypertension, in collaboration with the Southern African Hypertension Society and Servier, among other scientific societies. It is a public call for everyone to get their blood pressure (BP) checked. This non-invasive test takes five minutes, is free during May Measurement Month, and can help save lives. Professor Erika Jones, the president of the Southern African Hypertension Society, said, 'Hypertension is often called the 'silent killer' because it typically has no symptoms until significant damage has occurred. 'It is a leading cause of heart disease and stroke, accounting for nearly half of related deaths worldwide. Despite this, awareness, treatment and control remain alarmingly low.' The scale of the problem The statistics, as recorded in 2019, paint a concerning picture: • 4.06 billion adults were affected by high systolic blood pressure; • 1.3 billion adults (30-79 years) were affected by hypertension; • 10.8 million deaths were associated with raised blood pressure; • Approximately 60% of adults develop hypertension by 60 years of age; • Up to 90% of adults living to 80 are likely to develop hypertension; • Hypertension causes over 50% of heart disease, stroke and heart failure cases. SA faces an exceptionally high burden, with the South African Demographic and Health Survey (SADHS) reporting a hypertension prevalence of 46.0% in females and 44.0% in males above 18 years of age. Even more concerning, over 80% of people living with hypertension have uncontrolled blood pressure. This prevalence significantly exceeds the global average of 31.1%. ALSO READ: Local group walks to boost health The treatment gap A 'treatment cascade' exists for patients with hypertension. A report by the World Heart Federation (WHF), Roadmap for Hypertension, starts with those with high blood pressure, although many don't even know their status. Of those diagnosed, only a portion receive treatment, and fewer still achieve blood pressure control. Finally, patient adherence remains the biggest challenge. Effective prevention and detection of hypertension require a multi-faceted approach. This includes robust screening policies that include initial blood pressure screenings from the age of 18 and regular follow-ups and opportunistic screenings in various settings like workplaces, schools and community spaces. Population-wide interventions play a crucial role in prevention by promoting weight control through healthier diets (like the DASH diet), improving access to nutritious foods and implementing salt reduction strategies. 'Additionally, lifestyle interventions, such as adopting a balanced diet and increasing physical activity, are also essential in managing and reducing the risk of hypertension,' explained Jones. A WHF member survey across 46 countries showed 65% of the polled healthcare respondents reporting that their patients do not adhere to treatment plans, showing that even once the obstacles of detection and diagnosis are overcome, patients still struggle with maintaining their prescribed regimens. ALSO READ: Gauteng Health welcomes a new batch of counsellors Obstacles to prevention Despite knowing how to prevent and treat high blood pressure, many barriers stand in the way of success. These challenges affect patients and healthcare systems alike. For those diagnosed with hypertension, treatment brings its challenges – medication can be expensive, many people struggle to stay motivated for a condition with no obvious symptoms, there are cultural attitudes that sometimes discourage medical intervention, and daily pill routines can be complicated to maintain. ALSO READ: Make this month a healthy love story – Gauteng Health The healthcare systems face obstacles, too, including limited resources for widespread blood pressure screening; equipment shortages and inaccurate measurements; healthcare workers might have poor awareness or a misunderstanding of guidelines; and follow-up systems to monitor patient progress are often inadequate. With proper awareness of these challenges, patients and healthcare providers can work together to find practical solutions that make hypertension prevention and treatment more accessible for everyone. 'For more than 50 years, Servier has been committed to fighting high blood pressure – the 'silent killer' – that affects millions without warning. 'According to the World Health Organisation, this chronic illness claims over 11 million lives annually, making it humanity's largest epidemic. 'As non-communicable diseases like hypertension continue to rise, it solidifies the importance of collaborative public information campaigns like Because I Say So and May Measurement Month. 'We compel South Africans to take action and check their blood pressure. It has never been more crucial for public health,' says Virosha Deonarain, the medical manager at Servier. South Africans should go to their local pharmacies, clinics, or doctors to get tested for free in May. Find a participating pharmacy in your area and get the test today: At Caxton, we employ humans to generate daily fresh news, not AI intervention. Happy reading!
The Citizen
12-05-2025
- Health
- The Citizen
Know Your Blood Pressure This May Measurement Month
Know Your Blood Pressure This May Measurement Month This May Measurement Month, health experts are sounding the alarm on hypertension (HTN), a condition that affects billions worldwide yet remains dangerously underdiagnosed and undertreated. Alarmingly, a recent study found that 74% of patients are unaware that they are at risk of hypertension or are unaware of their hypertension status. World Hypertension Day is observed on May 17. ALSO READ: Ekurhuleni encourages public to use suggestion boxes at health facilities HTN is the most significant risk factor for cardiovascular disease (in SA. With cardiovascular disease ranking among the top 10 causes of death worldwide, detecting and controlling blood pressure has never been more critical. Uncontrolled hypertension can lead to serious health complications, significantly increasing the risk of heart attack, stroke, kidney failure and heart failure. It's also linked to a higher likelihood of developing dementia and can drastically reduce overall quality of life. These consequences contribute to increased mortality and morbidity, underscoring the importance of early detection, treatment and management of high blood pressure. May Measurement Month A public health campaign, Because I Say So is part of a global blood pressure screening initiative, May Measurement Month. Now in its ninth year, this collaborative campaign was initiated in response to the hypertension health crisis. It is led by the International Society of Hypertension, in collaboration with the Southern African Hypertension Society and Servier, among other scientific societies. It is a public call for everyone to get their blood pressure (BP) checked. This non-invasive test takes five minutes, is free during May Measurement Month, and can help save lives. Professor Erika Jones, the president of the Southern African Hypertension Society, said, 'Hypertension is often called the 'silent killer' because it typically has no symptoms until significant damage has occurred. The scale of the problem The statistics, as recorded in 2019, paint a concerning picture: • 4.06 billion adults were affected by high systolic blood pressure; • 1.3 billion adults (30-79 years) were affected by hypertension; • 10.8 million deaths were associated with raised blood pressure; • Approximately 60% of adults develop hypertension by 60 years of age; • Up to 90% of adults living to 80 are likely to develop hypertension; • Hypertension causes over 50% of heart disease, stroke and heart failure cases. SA faces an exceptionally high burden, with the South African Demographic and Health Survey (SADHS) reporting a hypertension prevalence of 46.0% in females and 44.0% in males above 18 years of age. Even more concerning, over 80% of people living with hypertension have uncontrolled blood pressure. This prevalence significantly exceeds the global average of 31.1%. ALSO READ: Ekurhuleni encourages public to use suggestion boxes at health facilities The treatment gap A 'treatment cascade' exists for patients with hypertension. A report by the World Heart Federation (WHF), Roadmap for Hypertension, starts with those with high blood pressure, although many don't even know their status. Of those diagnosed, only a portion receive treatment, and fewer still achieve blood pressure control. Finally, patient adherence remains the biggest challenge. Effective prevention and detection of hypertension require a multi-faceted approach. This includes robust screening policies that include initial blood pressure screenings from the age of 18 and regular follow-ups and opportunistic screenings in various settings like workplaces, schools and community spaces. A WHF member survey across 46 countries showed 65% of the polled healthcare respondents reporting that their patients do not adhere to treatment plans, showing that even once the obstacles of detection and diagnosis are overcome, patients still struggle with maintaining their prescribed regimens. ALSO READ: Media called to action in supporting health services across Ekurhuleni Obstacles to prevention Despite knowing how to prevent and treat high blood pressure, many barriers stand in the way of success. These challenges affect patients and healthcare systems alike. For those diagnosed with hypertension, treatment brings its challenges – medication can be expensive, many people struggle to stay motivated for a condition with no obvious symptoms, there are cultural attitudes that sometimes discourage medical intervention, and daily pill routines can be complicated to maintain. ALSO READ: Teenage pregnancy campaign clarified – Gauteng Health The healthcare systems face obstacles, too, including limited resources for widespread blood pressure screening; equipment shortages and inaccurate measurements; healthcare workers might have poor awareness or a misunderstanding of guidelines; and follow-up systems to monitor patient progress are often inadequate. With proper awareness of these challenges, patients and healthcare providers can work together to find practical solutions that make hypertension prevention and treatment more accessible for everyone. 'For more than 50 years, Servier has been committed to fighting high blood pressure – the 'silent killer' – that affects millions without warning. 'As non-communicable diseases like hypertension continue to rise, it solidifies the importance of collaborative public information campaigns like Because I Say So and May Measurement Month. 'We compel South Africans to take action and check their blood pressure. It has never been more crucial for public health,' says Virosha Deonarain, the medical manager at Servier. South Africans should go to their local pharmacies, clinics, or doctors to get tested for free in May. Find a participating pharmacy in your area and get the test today: At Caxton, we employ humans to generate daily fresh news, not AI intervention. Happy reading!
Yahoo
08-04-2025
- Business
- Yahoo
TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space
With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an unmet need in personalized cancer treatment, offering new hope for patients with limited options. As clinical evidence continues to support its efficacy and safety, TIBSOVO is positioned for strong growth in the oncology market, especially with expanding indications and global market penetration. LAS VEGAS, April 8, 2025 /PRNewswire/ -- DelveInsight's "TIBSOVO Market Size, Forecast, and Market Insight Report" highlights the details around TIBSOVO, the first and only targeted therapy approved for patients with previously treated IDH1-mutated cholangiocarcinoma. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of TIBSOVO. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Servier's TIBSOVO (ivosidenib) Overview TIBSOVO (ivosidenib) is a small molecule developed by Servier, acts as an isocitrate dehydrogenase-1 (IDH1) inhibitor. It is indicated for patients with a susceptible IDH1 mutation, which is identified through an FDA-approved test. Currently, TIBSOVO is approved for the treatment of newly diagnosed acute myeloid leukemia (AML), relapsed or refractory AML, relapsed or refractory myelodysplastic syndromes (MDS), and locally advanced or metastatic cholangiocarcinoma. According to Servier's pipeline, TIBSOVO is also being actively investigated for a range of additional indications, with key areas of exploration including solid tumors and hematological malignancies. Drug Name TIBSOVO (ivosidenib) Approved Year 2018 (R/RAML); 2019 (AML); 2021 (Cholangiocarcinoma); 2023 (R/R MDS) Molecule type Small molecule Developer Servier Primary Indication US: R/R AML, AML, Cholangiocarcinoma, R/R MDS EU: AML, Cholangiocarcinoma Mechanism of action IDH1 inhibitor Route of administration Oral Learn more about TIBSOVO projected market size for AML, cholangiocarcinoma, and MDS @ TIBSOVO Market Potential The oncology market has experienced significant growth in recent years, driven by advances in cancer research, the development of targeted therapies, and the increasing global prevalence of cancer. As the second-leading cause of death worldwide, cancer continues to pose a major public health challenge, creating a substantial demand for innovative treatments. The market is marked by a shift toward personalized medicine, where therapies are tailored to an individual's genetic profile, allowing for more effective and less toxic treatments. Immunotherapies, such as checkpoint inhibitors, CAR-T cell therapies, and oncolytic virus therapies, are at the forefront of these advancements, offering new hope to patients with previously untreatable cancers. Moreover, the oncology market is expanding due to the growing adoption of precision oncology and molecular diagnostics, which enable earlier and more accurate detection of cancer. This has led to increased investments in research and development, especially in areas like liquid biopsies, companion diagnostics, and next-generation sequencing. The demand for more effective and accessible cancer treatments is fueling innovation in both the pharmaceutical and biotechnology sectors, with numerous new drugs and therapies entering clinical trials and moving toward commercialization. As a result, the oncology market is poised to continue growing, with significant opportunities for breakthrough therapies in immuno-oncology, targeted treatments, and gene therapies. DelveInsight has expertise in the oncology market with an experienced team handling the oncology domain proficiently. DelveInsight has released a series of epidemiology-based market reports on Acute Myeloid Leukemia, Cholangiocarcinoma, and Myelodysplastic Syndrome. These reports include a comprehensive understanding of current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Gain deeper insights into these diseases with a customized report tailored to your needs. Connect with us today—our experts are ready to assist you! Emerging Competitors of TIBSOVO TIBSOVO faces significant competition in the newly diagnosed AML market from several alternative treatments. Oral therapies like VENCLEXTA (venetoclax), which inhibits BCL-2, and DAURISMO (glasdegib), which targets the hedgehog pathway, present strong contenders. Additionally, emerging therapies such as Lisaftoclax (Ascentage Pharma), another BCL-2 inhibitor, and gilteritinib (Astellas), a kinase inhibitor, are expected to further challenge TIBSOVO in the newly diagnosed AML space. In the R/R AML market, TIBSOVO competes with several therapies, including XOSPATA (gilteritinib), IDHIFA (enasidenib), and others. Emerging therapies such as Ziftomenib (Kura Oncology) and RVU-120 (Ryvu Therapeutics) are also expected to compete with TIBSOVO upon their approval. Ziftomenib, a small molecule developed by Kura Oncology, is currently in Phase I/II trials. In the relapsed/refractory (R/R) MDS market, TIBSOVO faces competition from therapies such as RYTELO (Imetelstat), an IV injection that inhibits oligonucleotide telomerase, and REBLOZYL (Luspatercept), a subcutaneous injection, among other treatment options. In the metastatic cholangiocarcinoma market, TIBSOVO faces relatively less competition, as there are few approved therapies. One such competitor is PEMAZYRE (pemigatinib), a kinase inhibitor that was approved in the US in 2020 and in Europe in 2021. Whereas, Tyra Biosciences' TYRA-200, an FGFR1/2/3 inhibitor, is in phase I stage of development that might be a threat to TIBSOVO one approved. To know more about the number of competing drugs in development, visit @ TIBSOVO Market Positioning Compared to Other Drugs Key Developmental Activities of TIBSOVO In October 2023, Servier announced that the FDA has approved TIBSOVO (ivosidenib tablets) for the treatment of IDH1-mutated R/R MDS. In May 2023, Servier announced that the European Commission has approved TIBSOVO as a targeted therapy in two indications: in combination with azacitidine for the treatment of adult patients with newly diagnosed AML with an isocitrate dehydrogenase-1 R132 mutation who are not eligible to receive standard induction chemotherapy; as well as in monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy. In May 2022, Servier announced FDA approval of TIBSOVO (ivosidenib tablets) in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia. In August 2021, Servier announced FDA approval for TIBSOVO (ivosidenib tablets) for the treatment of adult patients with previously treated, locally advanced, or metastatic cholangiocarcinoma with an IDH1 mutation as detected by an FDA-approved test. TIBSOVO is the first and only targeted therapy approved for patients with previously treated IDH1-mutated cholangiocarcinoma. In May 2019, Agios announced FDA approval of TIBSOVO (ivosidenib tablets) as monotherapy for newly diagnosed adult patients with IDH1 mutant acute myeloid leukemia not eligible for intensive chemotherapy. In July 2018, the FDA approved TIBSOVO (ivosidenib) for relapsed or refractory acute myeloid leukemia with an idh1 mutation. In February 2018, the FDA accepted a new drug application and granted priority review for ivosidenib in relapsed or refractory AML with an IDH1 mutation. In December 2017, Agios submitted an NDA to the FDA for ivosidenib for the treatment of patients with relapsed/refractory aml and an IDH1 mutation. TIBSOVO Patent Details TIBSOVO is a drug owned by Servier Pharmaceuticals. Currently, it is protected by 10 Orange book-listed patents filed from 2018 to 2023, out of which none have expired yet. It is also protected by ODE exclusivity for various indications. Discover how TIBSOVO is shaping the blood cancer treatment landscape @ TIBSOVO Side Effects TIBSOVO Market Dynamics In recent years, the therapeutic landscape has undergone significant changes, with promising approaches including immunotherapy, chemotherapy combined with targeted treatments, and the regulation of immune checkpoint-mediated signaling pathways. One such treatment, Ivosidenib, works by inducing the bone marrow to develop normal blood cells, helping to reduce the frequency of blood transfusions. Investment in the research and development of drugs has surged, contributing to a rich pipeline and forecasting promising opportunities in the treatment markets for AML and cholangiocarcinomas. Therapies like TIBSOVO have the potential to capture market attention due to their efficacy and innovation. As healthcare spending continues to rise globally, the pharmaceutical market is expected to expand, providing greater opportunities for market penetration by manufacturers and facilitating the development and distribution of new treatments. Despite progress in cancer treatment, significant gaps remain in understanding the full process that governs carcinogenesis and resistance to treatments, particularly in cancers like acute myeloid leukemia (AML). This highlights the need for more advanced research to address these challenges. Additionally, the limited biomarker testing for patients with the IDH1 mutation restricts the targeted patient pool, posing a challenge for therapies like TIBSOVO to achieve their expected market share. The increasing competition from emerging therapies, such as KEYTRUDA (pembrolizumab), IMFINZI (durvalumab), and the combination of Azacitidine + Venetoclax, further intensifies the pressure on TIBSOVO. Moreover, the difficulty in obtaining sufficient patient pools and diagnostic samples during disease recurrence presents significant hurdles to the effective development of translational research, potentially slowing progress in optimizing treatments. Dive deeper to get more insight into TIBSOVO's strengths & weaknesses relative to competitors @ TIBSOVO Market Drug Report Table of Contents 1 Report Introduction 2 TIBSOVO: Servier 2.1 Product Overview 2.2 Other Development Activities 2.3 Clinical Development 2.4 Clinical Trials Information 2.5 Safety and Efficacy 2.6 Product Profile 2.7 Market Assessment 2.7.1 The 7MM Analysis 2.7.1.1 Cost Assumptions and Rebate 2.7.1.2 Pricing Trends 2.7.1.3 Analogue Assessment 2.7.1.4 Launch Year and Therapy Uptake 2.7.2 The United States Market Analysis 2.7.3 EU4 and the United Kingdom Market Analysis 2.7.3.1 Germany 2.7.3.2 France 2.7.3.3 Italy 2.7.3.4 Spain 2.7.3.5 UK 2.7.4 Japan Market Analysis 2.8 Market Drivers 2.9 Market Barriers 2.10 SWOT Analysis 3 Key Cross of Marketed Competitors of TIBSOVO 4 Key Cross of Emerging Competitors of TIBSOVO Related Reports Acute Myeloid Leukemia Market Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key AML companies including Agios Pharmaceuticals, Abbvie, Jazz Pharmaceuticals, Astellas Pharma, Pfizer, Novartis Oncology, Daiichi Sankyo, AstraZeneca, Astex Pharmaceuticals, Inc., Chimerix, Takeda, Rafael Pharmaceuticals Inc., Delta-Fly Pharma, GlycoMimetics Incorporated, BerGenBio ASA, MacroGenics, Syndax Pharmaceuticals, Arog Pharmaceuticals, Forma Therapeutics, Sellas Life Sciences Group, Actinium Pharmaceuticals, Clear Creek Bio Inc., CellCentric Ltd., Biosight Ltd., Astex Pharmaceuticals, Inc., Curis, Inc., NexImmune Inc., Immunomedics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Incyte Corporation, Aprea Therapeutics, Immunicum, DCPrime BV, GT Biopharma, Inc., Hanmi Pharmaceutical Company Limited, Cardiff Oncology, Bio-Path Holdings, Actinium Pharmaceuticals, Aptevo Therapeutics, Synimmune GmbH, GEMoaB Monoclonals, ImmunoGen, Inc., AGC Biologics S.p.A., Precigen, Inc., Novartis Pharmaceuticals, Xencor, Inc., Novartis, Celgene, Bristol Myers Squibb, among others. Relapsed/Refractory Acute Myeloid Leukemia Market Relapsed/Refractory Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key R/R AML companies including Agios Pharmaceuticals, Abbvie, Jazz Pharmaceuticals, Astellas Pharma, Pfizer, Novartis Oncology, Daiichi Sankyo, AstraZeneca, Astex Pharmaceuticals, Inc., Chimerix, Takeda, Rafael Pharmaceuticals Inc., Delta-Fly Pharma, GlycoMimetics Incorporated, BerGenBio ASA, MacroGenics, Syndax Pharmaceuticals, Arog Pharmaceuticals, Forma Therapeutics, Sellas Life Sciences Group, Actinium Pharmaceuticals, Clear Creek Bio Inc., CellCentric Ltd., Biosight Ltd., Astex Pharmaceuticals, Inc., Curis, Inc., NexImmune Inc., Immunomedics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Incyte Corporation, Aprea Therapeutics, Immunicum, DCPrime BV, GT Biopharma, Inc., Hanmi Pharmaceutical Company Limited, Cardiff Oncology, Bio-Path Holdings, Actinium Pharmaceuticals, Aptevo Therapeutics, Synimmune GmbH, GEMoaB Monoclonals, ImmunoGen, Inc., AGC Biologics S.p.A., Precigen, Inc., Novartis Pharmaceuticals, Xencor, Inc., Novartis, Celgene, Bristol Myers Squibb, among others. Myelodysplastic Syndrome Market Myelodysplastic Syndrome Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key MDS companies such as Bristol-Myers Squibb, Astex Pharmaceutical, Taiho Oncology, Fibrogen, AbbVie, Gilead Sciences, Novartis, Syros Pharmaceuticals, Takeda, Pfizer, Geron Corporation, Karyopharm Therapeutics, Antengene Corporation, BerGenBio ASA, Jazz Pharmaceuticals, Aprea Therapeutics, Sanofi, Medac, among others. Cholangiocarcinoma Market Cholangiocarcinoma Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cholangiocarcinoma companies such as AstraZeneca, Decalth Systems, Basilea Pharmaceutica, Taiho Oncology, Eisai Pharmaceuticals, TransThera Sciences, Incyte Corporation, Roche, Agios Pharmaceuticals, Servier Pharma, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP
